Dune Medical Devices of Paoli has won FDA approval of an updated version of its flagship product, MarginProbe, a medical device that enables real-time detection of cancer at the surface of excised tissue specimens during breast-conserving cancer surgery.

Surgeon feedback, innovative design ideas and superior miniaturization engineering were the driving forces behind the development of MarginProbe 1.2, the firm says.

“Our goal in offering this update is to provide surgeons with the most effective, easy-to-use product when they walk into a lumpectomy case,” said Dan Hashimshony, CEO of Dune Medical Devices. “Once the MarginProbe demonstrated national success across all territories, we began enhancing the usability for surgeons while offering simpler handling. Despite the fact that we offer the only product dedicated to the pressing need for intraoperative margin assessment in breast cancer surgery, we always knew it’s critical we constantly listen to our loyal and growing customer base and do our best to offer them further innovation.”

More information about the product can be found here.

Dr. Hashimshony founded Dune Medical Devices in 2002. Hashimshony said his technology offers surgeons and radiologists the real time ability to identify cancerous tissues and react immediately, and promises a broad range of surgical and diagnostic applications. The privately held firm also has an office in Israel.

_______

Top photo credit: osxapple via photopin cc